NEWS

BiondVax, NIAID kick off phase 2 universal flu vaccine study in U.S.

April 11, 2018

Already gearing up for a late-stage universal flu vaccine test in European countries, BiondVax has attracted its first participant to a phase 2 study sponsored by the National Institute of Allergy and Infectious Diseases.

Read More

Mylan to Acquire the Global Marketing Rights to Glatiramer Acetate Product through Mapi Pharma

April 10, 2018

Once approved, this product could represent a significant milestone for patients with relapsing-remitting multiple sclerosis.

Read More

Ayala notches up $17M in financing to push BMS drug into phase 2

April 10, 2018

Israeli biotech Ayala Pharmaceuticals, founded last year as a development vehicle for two of Bristol-Myers Squibb’s cancer candidates, has raised $17 million in a series A financing.

Read More

Pharma Two B Doses First Patients in Early-stage Parkinson’s Phase 3 Trial

February 12, 2018

Israel’s Pharma Two B has dosed the first patients in a Phase 3 trial to evaluate the safety and efficacy of its drug candidate P2B001 to treat early-stage Parkinson’s disease.

Read More

Additional Strategic Funding for CartiHeal’s Ongoing AGILI-C™ IDE Clinical Study

January 31, 2018

KFAR SABA, Israel & DURHAM, N.C.–(BUSINESS WIRE)–CartiHeal, developer of the proprietary Agili-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints, has secured a $2.5M investment from Bioventus, a global leader in orthobiologics – reflecting the growing interest in CartiHeal’s technology.

Read More

Pharma Two B Ltd. Closes $30 Million Financing Round

January 23, 2018

REHOVOTH, Israel, Feb. 27, 2017 /PRNewswire/ — Pharma Two B Ltd., a privately held biopharmaceutical company focused on developing treatments for Parkinson’s disease, announced today it has completed its third round of financing. The $30MM funding round was led by Israel Biotech Fund (IBF) which identified the company, led the due diligence, and syndicated with leading US and…

Read More

Marius Nacht to invest $20m in Regenera

January 2, 2018

aMoon Partners, controlled and managed by by Check Point Software Technologies Ltd. (Nasdaq: CHKP) cofounder Marius Nacht, together with Dr. Yair Schindel, is likely to invest $20 million more in pharma company Regenera, in which InterCure Ltd. (TASE: INCR-L) owns a 23.48% stake. According to the proposal, aMoon will invest $10 million now and $10 million more as needed.

Read More

Nacht, Harel Insurance invest in personalized cancer treatment

December 7, 2017

Ayala Pharmaceuticals has bought rights from international company Bristol-Myers Squibb (BMS) to develop a personalized treatment for cancer. Ayala, founded a few months ago for this purpose, is an initiative by the Israel Biotech Fund, led by Dr. David Sidransky, Dr. Yuval Cabilly, and Ido Zairi. The fund recruited the aMoon Partners fund (led by Check…

Read More

Ayala Pharmaceuticals, Founded by Israel Biotech Fund, aMoon and Harel Insurance, Enters Exclusive Worldwide License Agreement with Bristol-Myers Squibb (BMS) to Develop Cancer Treatments

December 6, 2017

REHOVOT, Israel–(BUSINESS WIRE)–Ayala Pharmaceuticals, a biopharmaceutical company dedicated to developing targeted cancer therapies, announced today that they have entered into an exclusive worldwide license agreement with Bristol-Myers Squibb for two gamma secretase inhibitors in development for the treatment of cancers with altered Notch genes.

Read More

Mapi Pharma Ltd. Announces Closing of $10 Million Investment

August 17, 2017

Mapi Pharma Ltd., a privately held, fully integrated, clinical stage biopharmaceutical company has completed an investment round of $10 million by aMoon Fund. aMoon Fund is an Israeli investment firm focused on innovative Israeli healthcare and life science ventures, founded by Marius Nacht and Dr. Yair Schindel.

Read More

Ibex Obtains CE-IVD Mark for AI-powered Cancer Detection

February 27, 2020

Ibex’s Galen™ Prostate solution demonstrates outstanding results in a blinded study and supports pathologists in providing accurate diagnosis, enhanced lab efficiency and quality control.

Read More

Karius raises $165 million for its liquid biopsy technology identifying diseases with a blood draw

February 24, 2020

While the new money may have been raised under the looming threat of Covid 19, the company’s technology is already being used to test for infection-causing pathogens in immunocompromised pediatric patients, and for potential causes of complex pneumonia, fungal infections and endocarditis, according to a statement from the company.

Read More

Interview: Healthtech Is Israel’s Next Growth Engine, Says Venture Capitalist

February 21, 2020

Yair Schindel was a decorated army medic, a doctor, an entrepreneur, and the head of Israel’s National Digital Bureau. Now, he manages Israeli venture capital fund aMoon and wants to turn Israel into a healthtech empire.

Read More

Life Sciences Venture Fund aMoon Invests $5 Million in Cancer Drug Company

December 24, 2019

Israel-based life sciences, healthcare, and technology venture capital firm aMoon, together with an unnamed private investor, invested $5 million in cancer drug startup NanoGhosts, aMoon told Calcalist. This is NanoGhosts’s first investment.

Read More

Seer Announces $55 Million in Series D Equity Financing Bringing in New Investors aMoon Fund and T. Rowe Price Funds

December 19, 2019

Capital will enable continued advancement of novel Proteograph™ platform and commercialization of first-in-class proteomics products

Read More

Newly Merged Voice Analysis Startups Healthymize and Beyond Verbal Raise $9 Million

December 10, 2019

The new entity, Vocalis Health, will develop technology for the voice-based analysis and detection of health issues such as heart and respiratory conditions and depression

Read More

Steven Mnuchin, Israeli Health Officials Discuss Establishment of Israeli FDA Branch

October 29, 2019

The FDA, which approves all medical devices and formulations in the U.S., has very few branches outside of the U.S.

Read More

aMoon invests in $80m Adicet Bio financing round

October 3, 2019

Based on technology developed by the Technion’s Prof. Yoram Reiter, Adicet Bio is developing allogeneic cell therapies for cancer using innovative gamma delta T cells.

Read More

MDClone, Developer of First Healthcare Synthetic Data Engine, Raises $26 Million

August 22, 2019

aMoon Leads New Investment Round with Participation from OrbiMed and Lightspeed Venture Partners.

Read More

Israel’s 10 ‘Hottest’ Startups In 2019, According to WIRED Magazine

August 21, 2019

Tel Aviv – has “the highest number of startups per capita in the world…with more than 6,000, of which 18 are unicorns…more than 100 venture capital funds, plus hundreds of accelerators and co-working places.”

Read More